Extending natalizumab up to 8 weeks shown safe and effective in patients with MS
In a study of 1,964 patients with multiple sclerosis (MS) led by researchers at the NYU Langone Multiple Sclerosis Comprehensive Care Center, extending the dose of natalizumab from 4 weeks up to 8 weeks was shown to be well-tolerated ...
Apr 20, 2015
0
9